Betta Pharmaceuticals Co., Ltd. (SHE: 300558)

Betta Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	2,718	2,417	2,342	2,206	1,824	1,502
Other Revenue	39.41	39.41	34.18	40.05	46.19	52.1
Revenue	2,757	2,456	2,377	2,246	1,870	1,554
Revenue Growth (YoY)	-0.01%	3.35%	5.82%	20.08%	20.36%	26.94%
Cost of Revenue	490.85	404.48	268.69	174.44	138.9	105.23
Gross Profit	2,266	2,052	2,108	2,071	1,731	1,449
Selling, General & Admin	1,279	1,116	1,234	1,141	946.77	819.78
Research & Development	556.24	640.14	699.9	565.95	362.85	326.36
Other Operating Expenses	34.07	10.72	-34.51	15.24	6.99	-9.2
Operating Expenses	1,860	1,772	1,901	1,723	1,317	1,137
Operating Income	406.58	279.88	206.96	348.77	414.79	311.78
Interest Expense	-44.31	-54.95	-195.8	-15.78	-39.86	-48.06
Interest & Investment Income	8.03	10.23	10.88	33.35	298.46	3.29
Currency Exchange Gain (Loss)	6.72	6.72	9.55	-3.63	-8.42	1.33
Other Non Operating Income (Expenses)	-74.35	-4.96	-9	-0.84	2.03	-1.37
EBT Excluding Unusual Items	302.67	236.92	22.59	361.88	666.99	266.97
Gain (Loss) on Sale of Investments	41.31	-13.67	-20.62	1.01	-12.42	-0.8
Gain (Loss) on Sale of Assets	0.62	-0.01	88.61	0.07	-1.7	0.29
Asset Writedown	-1.07	-1.07	-3.01	-0.03	-	-
Other Unusual Items	118.58	99.9	-	27.01	13.79	-
Pretax Income	462.11	322.07	87.57	389.93	666.66	266.46
Income Tax Expense	17.47	-11.54	-37.19	10.37	65.58	40.62
Earnings From Continuing Operations	444.65	333.62	124.76	379.56	601.09	225.84
Minority Interest in Earnings	14.92	14.42	20.66	3.51	5.27	4.98
Net Income	459.57	348.03	145.42	383.07	606.36	230.82
Net Income to Common	459.57	348.03	145.42	383.07	606.36	230.82
Net Income Growth	32.32%	139.33%	-62.04%	-36.83%	162.70%	38.37%
Shares Outstanding (Basic)	420	418	416	416	404	401
Shares Outstanding (Diluted)	423	421	416	416	407	403
Shares Change (YoY)	0.53%	1.10%	-0.02%	2.32%	1.09%	1.35%
EPS (Basic)	1.09	0.83	0.35	0.92	1.50	0.58
EPS (Diluted)	1.09	0.83	0.35	0.92	1.49	0.57
EPS Growth	31.92%	137.47%	-62.01%	-38.26%	161.40%	35.71%
Free Cash Flow	310.7	-181.79	-703.8	-231.75	-39.81	-65.34
Free Cash Flow Per Share	0.73	-0.43	-1.69	-0.56	-0.10	-0.16
Dividend Per Share	0.170	0.170	0.070	0.250	0.310	0.190
Dividend Growth	142.86%	142.86%	-72.00%	-19.35%	63.16%	72.73%
Gross Margin	82.20%	83.53%	88.69%	92.23%	92.57%	93.23%
Operating Margin	14.75%	11.39%	8.71%	15.53%	22.18%	20.06%
Profit Margin	16.67%	14.17%	6.12%	17.06%	32.42%	14.85%
Free Cash Flow Margin	11.27%	-7.40%	-29.61%	-10.32%	-2.13%	-4.21%
EBITDA	743.57	578.14	453.58	517.89	569.95	454.54
EBITDA Margin	26.97%	23.54%	19.08%	23.06%	30.47%	29.25%
D&A For EBITDA	336.99	298.26	246.62	169.12	155.16	142.76
EBIT	406.58	279.88	206.96	348.77	414.79	311.78
EBIT Margin	14.75%	11.39%	8.71%	15.53%	22.18%	20.06%
Effective Tax Rate	3.78%	-	-	2.66%	9.84%	15.24%
Revenue as Reported	2,757	2,456	2,377	2,246	1,870	1,554
Advertising Expenses	-	428.62	414.75	459.29	376.61	264.62

Source: S&P Capital IQ. Standard template. Financial Sources.